Your session is about to expire
← Back to Search
Extended-release Buprenorphine: Buttocks for Opioid Use Disorder
Study Summary
This trial looks at different injection sites for extended-release buprenorphine to treat opioid use disorder. Results help determine which sites are best for long-term use.
- Opioid Use Disorder
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a significant problem with using drugs or alcohol, except for opioids, tobacco, cannabis, or moderate alcohol use.You are allergic to BUP or any part of the ATRIGEL Delivery System.You have recently had thoughts of hurting yourself or have attempted suicide in the past six months.You have a personal or family history of a heart condition called congenital QT prolongation or take certain medications that can affect your heart rhythm.
- Group 1: Extended-release Buprenorphine: Buttocks
- Group 2: Extended-release Buprenorphine: Abdomen
- Group 3: Extended-release Buprenorphine: Upper Arm
- Group 4: Extended-release Buprenorphine: Thigh
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the trial inclusive of individuals aged sixty and older?
"According to the criteria for study enrolment, participants must be between 18 and 65 years of age."
To what extent is Extended-release Buprenorphine: Upper Arm treatment safe for patients?
"We have assigned Extended-release Buprenorphine's safety a score of 3, owing to it having reached Phase 4 trials and thus earned approval."
Are there any vacancies still available to join this research endeavor?
"Affirmative. The information on clinicaltrials.gov highlights that this medical experiment is actively seeking volunteers, with the initial post made on March 1st 2023 and most recent update from March 3rd 2023. A total of 80 subjects are required to be recruited at 2 different sites."
What is the scope of this experiment in terms of participants?
"That is accurate. According to information found on clinicaltrials.gov, this research project was first announced on March 1st 2023 and has been actively searching for 80 volunteers across 2 medical centres since then."
Which individuals meet the criteria for participating in this research?
"This trial is searching for 80 individuals with a moderate to severe opioid use disorder aged between 18 and 65. To qualify, potential participants must have signed an informed consent form (ICF) demonstrating their willingness to comply with the restrictions laid out in the document; be of either gender; possess a body mass index falling between 18-33 kg/m^2.; not already be receiving treatment or medication related to OUD other than those administered by this study; and agree not to take any buprenorphine containing products throughout its duration."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger